📰 Preserved Ejection Fraction News
Preserved Ejection Fraction News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Preserved Ejection Fraction. Real-time updates on events, politics, business and more.
April 24, 2024
1. In this randomized controlled trial, long-term beta-blockers did not impact all-cause mortality among patients with preserved left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) and early angiography. 2. Long-term beta-blocker therapy was not associated with a higher risk of adverse events compared to no beta-blocker. Evidence Rating Level: 1 (Excellent) Study
April 23, 2024
1. In this randomized controlled trial, semaglutide was more effective in reducing heart failure-related symptoms and physical limitations in patients with obesity-related heart failure and type 2 diabetes mellitus (T2DM) than placebo. 2. Patients with obesity-related heart failure and T2DM exhibited greater weight loss with semaglutide than placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Heart
April 10, 2024
Patients who have suffered a minor heart attack do not benefit from beta-blockers, according to a major new study that may change guidelines for cardiac care.
April 7, 2024
Wegovy, a popular weight loss drug, seems to provide more health benefits for people who have diabetes and a common kind of heart failure than just helping take off the pounds, according to a new study.
April 3, 2024
In gearing up for its Annual Scientific Session, ACC.24, amidst the 75th anniversary of the organization, the American College of Cardiology (ACC) has planned a full range of educational programming, special events and peer networking scheduled throughout the April 6-8 event in Atlanta, GA.
March 28, 2024
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Expansion of U.S.
February 29, 2024
The complete list of late-breaking clinical science to be presented at THT 2024: Technology and Heart Failure Therapeutics is now available online. An internat
February 29, 2024
The complete list of late-breaking clinical science to be presented at THT 2024: Technology and Heart Failure Therapeutics is now available online. An internat
February 6, 2024
By Rob Curran Shares of Tenax Therapeutics surged after the drug developer said a patent application was accepted for one of its product candidates in the...